BRÈVE

sur DocMorris AG (isin : CH0042615283)

DocMorris Reports Strong Q1 2026 Revenue Growth

DocMorris AG has reported a significant 10.7% increase in external revenue for Q1 2026. Revenue climbed to CHF 318.1 million, driven by a notable 30.4% rise in Rx and a 6.5% increase in Non-Rx sales. Digital Services soared by 63.1%, showcasing the strength of DocMorris' digital health platform.

CEO Walter Hess highlighted the continuous revenue momentum from late 2025 into early 2026, emphasizing strong performance in all business areas. CFO Daniel Wüest noted an improved EBITDA by CHF 9.8 million compared to the previous year, setting the company on track for EBITDA break-even by 2026.

The company also reported an increase in its active customer base to 12.6 million. Across Germany, revenue grew by 11.1%, while Europe saw a modest 2.9% growth. With an adjusted EBITDA of minus CHF 6.3 million, DocMorris reaffirms its medium-term targets and anticipates reaching free cash flow break-even in 2027.

R. E.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de DocMorris AG